The presentation will discuss challenges and opportunities of oncology CAR cell therapy FIH dose selection. We conducted meta analysis to evaluate preclinical to clinical dose translation using empirical scaling methods, followed by more detailed analysis on the key factors that drive preclinical efficacy and the opportunities to translate into the clinic.
Learning Objectives:
Upon completion, participant will be able to appreciate unique pharmacokinetic and pharmacodynmaic properties of CAR cell therapy.
The presentation will introduce an empirical dose translation method based on outcomes from meta-analysis of literature CAR cell therapy preclinical and clinical doses.
The presentation will also explore mechanistic quantitative analysis approach to enable the preclinical to clinical translation effort
